You are here

P&T® Journal contents for June 2009

Features

Health Policy
Issues of Interest to P&T Committees
Increasing generic drug use, legalizing drug reimportation, establishing electronic health records, and using comparative effectiveness research to a greater extent are possible changes that might take place under the new administration.
C. Lee Ventola, MS
Red yeast rice is a dietary supplement with the same chemical structure as ­lovastatin (Mevacor), but it is not regulated by the FDA. Although patients have used it to reduce cholesterol levels, some serious problems (muscular atrophy, rhabdomyolysis) can result. Inconsistent quality and toxigenic ingredients can cause additional complications.
Matthew Klimek, PharmD, Shan Wang, PharmD, and Adeleye Ogunkanmi, PharmD
Meeting Highlights
Some of the topics covered at the ASH sessions were fixed-dose combinations (Lotrel, Lotensin, Benicar HCT, and Azor) as well as an endothelin receptor agonist (darusentan). Therapies presented at the AUA meeting included dutasteride (Avodart) for reducing the risk of prostate cancer; a topical gel of oxybutynin chloride (Gelnique) for treating patients with overactive bladder; and silodosin (Rapaflo) for decreasing symptoms of benign prostatic hyperplasia.
Walter Alexander
Golimumab (Simponi) for the treatment of arthritis, Benzyl Alcohol Lotion 5% for patients with head lice, and artemether/lumefantine (Coartem/Riamet) tablets for uncomplicated malaria are discussed.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
David B. Nash, MD, MBA, describes survey results indicating that when it comes to improving health care, the old adage still applies: what gets paid for gets accomplished.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, warns about the ­dangers of patients tampering with infusion pumps in the hospital.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Congress Likely to Ban Exclusion Payments
Stephen Barlas discusses ­possible legislation that might limit the ability of brand-name drug companies to delay the introduction of generic competitors.
Stephen Barlas
From Creon to testosterone gel, P&T presents the latest studies about FDA approvals, new indications, alerts, and industry updates.
Drug Forecast
The authors review a C1 esterase inhibitor, Cinryze, for prophylaxis against hereditary angioedema attacks.
Craig Cocchio, PharmD, and Nino Marzella, BS, MS, PharmD